Bromo‐ and Extra‐Terminal (BET) protein inhibitor, which suppresses TNF‐α secretion by M1‐type macrophage, cancer cell proliferation, and VEGF‐A secretion, improves antitumor response when combined with anti‐CTLA‐4 treatment. This evidence concerns the gene TNF and cancer.